PA
BMRN icon

Perceptive Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Perceptive Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-200,000
Closed -$750K – 117
2019
Q3 		$750K Buy
+200,000
New +$15.4M 0.02% 93

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Perceptive Advisors's BMRN Position: Q3 2023 in Review

Perceptive Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 263,207 shares — an estimated $22.8M sold.

Perceptive Advisors first reported a position in BMRN in Q3 2016 and held it in 9 quarters. The position peaked at $104M in Q4 2021. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

  • Perceptive Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Perceptive Advisors sold 263,207 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $22.8M.
  • Perceptive Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 9 quarters.
  • Perceptive Advisors's BioMarin Pharmaceuticals position peaked at $104M in Q4 2021.
  • 519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.